摘要
新型冠状病毒肺炎(COVID-19)疫情对全球供应链造成了极大的冲击和破坏。在供给端,制造业停工停产,影响国际往来和贸易,进而又影响到其他国家的货物生产。这种对供求两端均造成破坏的情况复杂且少见,无疑对货币和财政政策的制定带来更大挑战。该文从COVID-19疫情对医药产业创新发展的影响、我国"十三五"生物医药发展的认识、发展监管科学提高科学监管能力推进生物医药创新发展和构建国内国际双循环互促生物医药发展新格局等方面分析,结合存在的问题,提出建立符合促进生物医药发展需求的国内国际双循环格局,立足于满足人民健康需求的医药产业结构的国内大循环,发挥比较优势,协同推进强大国内医药市场和医药贸易发展,以国内大循环吸引全球资源要素。应改善政府监管体制和企业管理水平,推进医药健康产品的高质量、高效率发展。
The outbreak of coronavirus disease 2019(COVID-19)has made a tremendous impact and destruction to the global supply chain.The shutdown of the manufacturing industry on the supply side affects international trade,which in turn affects the production of goods in other countries.This kind of damage to both sides of supply and demand is complex and rare,which brings greater challenges to the formulation of monetary and fiscal policy.This paper analyzes from four aspects:the impact of the COVID-19 epidemic on the innovation and development of the pharmaceutical industry,the understanding of biomedical development in China during the 13th Five-Year Plan period,the promotion of the innovation and development of biomedicine by developing regulatory science and improving scientific regulatory capacity,and the construction of a new pattern of domestic and international dual-cycle mutual promotion of biomedical development.Based on the existing problems,it is suggested that we should establish a domestic and international dual-cycle pattern in line with the development needs of biomedicine.Based on the domestic economy cycle of the pharmaceutical industrial structure to meet the needs of people’s health,we should give full play to comparative advantages,promote the development of the powerful domestic pharmaceutical market and pharmaceutical trade,and attract global resource elements with the domesfic economy cycle.The government supervision system and the management level of enterprises should be improved to promote the high-quality and high-efficiency development of medical and health products.
作者
刘昌孝
LIU Changxiao(Tianjin Institute of Pharmaceutical Research·State Key Laboratory of Drug Delivery Technology and Pharrnacokinetics·Tianjin Binhai Center for Food and Drug Regulatory Science,Tianjin,China 300301)
出处
《中国药业》
CAS
2021年第1期1-8,共8页
China Pharmaceuticals
基金
中国工程院咨询研究项目[2018-XY-39]。
关键词
生物医药
创新发展
双循环战略
监管科学
疫情防控
biomedicine
innovative development
dual-cycle strategy
regulatory science
epidemic prevention and control